These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35889320)

  • 41. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies).
    Ackaert O; McDougall D; Pérez-Ruixo C; Pérez-Ruixo JJ; Jezorwski J; Crauwels HM
    AAPS J; 2021 Jun; 23(4):82. PubMed ID: 34100149
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
    De Clercq E
    Biochem Pharmacol; 2016 Nov; 119():1-7. PubMed ID: 27133890
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
    Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
    Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner.
    Lade JM; To EE; Hendrix CW; Bumpus NN
    EBioMedicine; 2015 Sep; 2(9):1145-52. PubMed ID: 26501112
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of a weekly transdermal delivery system of tenofovir alafenamide in hairless rats.
    Jiang Y; Gao X; Singh ON; Zhang W; Agrahari V; Peet MM; Clark MR; Doncel GF; Banga AK
    Int J Pharm; 2020 May; 582():119342. PubMed ID: 32315746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
    Lanier ER; Ptak RG; Lampert BM; Keilholz L; Hartman T; Buckheit RW; Mankowski MK; Osterling MC; Almond MR; Painter GR
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2901-9. PubMed ID: 20439609
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics of Tenofovir Alafenamide, Tenofovir, and Emtricitabine Following Administration of Coformulated Emtricitabine/Tenofovir Alafenamide in Healthy Japanese Subjects.
    Yamada H; Yonemura T; Nemoto T; Ninomiya N; Irie S
    Clin Pharmacol Drug Dev; 2019 May; 8(4):511-520. PubMed ID: 30325567
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Tenofovir alafenamide fumarate - a new generation of tenofovir].
    Snopková S; Havlíčková K; Husa P
    Klin Mikrobiol Infekc Lek; 2016 Sep; 22(3):111-117. PubMed ID: 27907972
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epithelial Cells and Fibroblasts from the Human Female Reproductive Tract Accumulate and Release TFV and TAF to Sustain Inhibition of HIV Infection of CD4+ T cells.
    Shen Z; Rodriguez-Garcia M; Patel MV; Bodwell J; Wira CR
    Sci Rep; 2019 Feb; 9(1):1864. PubMed ID: 30755713
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.
    Callebaut C; Liu Y; Babusis D; Ray A; Miller M; Kitrinos K
    PLoS One; 2017; 12(2):e0169948. PubMed ID: 28182625
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
    Imaz A; Podzamczer D
    Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
    Sax PE; Rockstroh JK; Luetkemeyer AF; Yazdanpanah Y; Ward D; Trottier B; Rieger A; Liu H; Acosta R; Collins SE; Brainard DM; Martin H;
    Clin Infect Dis; 2021 Jul; 73(2):e485-e493. PubMed ID: 32668455
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+ T-cells and macrophages from demographically diverse donors.
    Bam RA; Birkus G; Babusis D; Cihlar T; Yant SR
    Antivir Ther; 2014; 19(7):669-77. PubMed ID: 24625459
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Octadecyloxyethyl benzyl tenofovir: A novel tenofovir diester provides sustained intracellular levels of tenofovir diphosphate.
    Beadle JR; Aldern KA; Zhang XQ; Valiaeva N; Hostetler KY; Schooley RT
    Antiviral Res; 2019 Nov; 171():104614. PubMed ID: 31550449
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial.
    Thurman AR; Schwartz JL; Cottrell ML; Brache V; Chen BA; Cochón L; Ju S; McGowan I; Rooney JF; McCallister S; Doncel GF
    EClinicalMedicine; 2021 Jun; 36():100893. PubMed ID: 34041459
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tenofovir Alafenamide.
    Gibson AK; Shah BM; Nambiar PH; Schafer JJ
    Ann Pharmacother; 2016 Nov; 50(11):942-952. PubMed ID: 27465879
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Establishment of intracellular tenofovir-diphosphate as the key determinant for in vitro-in vivo translation of antiviral efficacy.
    Ma B; Barth A; McHale CM; Lai MT
    Antiviral Res; 2018 Mar; 151():1-3. PubMed ID: 29337165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.
    Dumond JB; Greene SA; Prince HMA; Chen J; Maas BM; Sykes C; Schauer AP; Blake KH; Nelson JAE; Gay CL; Kashuba ADM; Cohen MS
    Antivir Ther; 2019; 24(1):45-50. PubMed ID: 30375984
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of tenofovir monobenzyl ester phosphonoamidate prodrugs with improved anti-hepatitis B virus activity and intrahepatic tenofovir enrichment.
    Sun X; Song L; Lin L; Ding A; Wang C; Ma X; Zhou S; Cai J; Tang H
    Bioorg Med Chem; 2024 Feb; 99():117607. PubMed ID: 38246114
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tenofovir alafenamide does not inhibit mitochondrial function and cholesterol biosynthesis in human T lymphoblastoid cell line.
    Li M; Zhou L; Dorsey HG; Musoff C; Jnr DA; Schoen N; Djan K; Paintsil E
    Antiviral Res; 2020 Nov; 183():104948. PubMed ID: 32980447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.